Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 74Breast Neoplasms 70Rectal Neoplasms 51Stomach Neoplasms 45Glioblastoma 45Esophageal Neoplasms 42Colorectal Neoplasms 37Lung Neoplasms 35Brain Neoplasms 35Squamous Cell Carcinoma of Head and Neck 32Pancreatic Neoplasms 31Glioma 27Neoplasms 26Sarcoma 24Neoplasm Metastasis 23Astrocytoma 22Head and Neck Neoplasms 21Carcinoma, Hepatocellular 19Esophageal Squamous Cell Carcinoma 16Colonic Neoplasms 16Recurrence 15Ovarian Neoplasms 15Melanoma 15Gliosarcoma 15Central Nervous System Neoplasms 15Urinary Bladder Neoplasms 13Oligodendroglioma 13Uterine Cervical Neoplasms 12Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 11

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11130-nm albumin-bound paclitaxel 11Sunitinib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Carcinoma × Surgical Procedures, Operative × Clear all
NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Emory University

Phase 1 Recruiting
40 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT03800134 2025-06-11

AEGEAN

AstraZeneca

Phase 3 Active not recruiting
825 enrolled 1 FDA
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05144100 2021-12-03

SCOPE

Tata Memorial Centre

Phase 2/3 Not yet recruiting
498 enrolled
Tumor-Agnostic

Carcinoma

NCT01218048 2018-08-16

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

Phase 2 Completed
40 enrolled 14 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma

NCT00191308 2011-10-21

Molecular Profiling in Lung Cancer Patients

Eli Lilly and Company

Phase 2 Completed
30 enrolled 11 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡